title: Cytokine fusion protein treatment.
abstract: Mice suffering from melanoma can be cured by treatment with a recombinant antibody-lymphotoxin-alpha fusion protein. In order to characterize the involvement of T cells in this syngeneic tumor model, the T cell receptor repertoire was analyzed both quantitatively and qualitatively. In this connection, quantitative analysis of the T cell receptors displayed only a modest overexpression in some of the variable beta chain families over the course of therapy. Clonotypic mapping, however, revealed a marked increase in the number of clonally expanded T cells among the tumor-infiltrating T cells, suggesting a specific activation.
authors.affiliation: Department of Dermatology, Julius Maximilians University, Würzburg, Germany.
authors.forename: David
authors.initials: D
authors.lastname: Schrama
authors.forename: Per thor
authors.initials: Pt
authors.lastname: Straten
authors.forename: Eva-Bettina
authors.initials: EB
authors.lastname: Bröcker
authors.forename: Ralph A
authors.initials: RA
authors.lastname: Reisfeld
authors.forename: Jürgen C
authors.initials: JC
authors.lastname: Becker
mesh_terms: D000818:Animals; D002999:Clone Cells; D016207:Cytokines / Q000627:therapeutic use*; D008233:Lymphotoxin-alpha / Q000627:therapeutic use; D008546:Melanoma, Experimental / Q000628:therapy*; D051379:Mice; D008810:Mice, Inbred C57BL; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013601:T-Lymphocytes / Q000276:immunology; D014407:Tumor Cells, Cultured
chemical_list: D016207:Cytokines; D008233:Lymphotoxin-alpha; D011993:Recombinant Fusion Proteins